Clinical trial · Observational
Role of PET/CT With Fluorine-18 Tracers of Bone Metastases in Prostate Cancer
Role of PET/CT With Fluorine-18 Tracers and of Diffusion Weighted Whole-body MRI in the Early Detection of Bone Metastases in Prostate Cancer
NCT01501630CI-TRIAL-00019450FLUPROSTICcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Compare PET/CT and MRI for the early detection of bone metastases of prostate cancer: diagnostic performance and impact on the patient management.Determine the lowest cost strategy according to the precise clinical circumstances.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| performance of PET/CT and whole-body MRI | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- PET/CT and MRI
- description
- all patients will benefit from PET/CT and MRI
- interventionNames
- Device: performance of PET/CT and whole-body MRI
Primary outcomes (1)
- measure
- bone metastases
- timeFrame
- within 6 months
- description
- Follow up data (histology, imaging, PSA levels) during 6 months to determine the standard of truth and the adequacy of the management decided on basis of imaging modalities.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 * Histologically proven prostate cancer. * Abnormal plasmatic level of prostate specific antigen dating less than 3 months, initial Gleason score available * Written informed consent. Exclusion Criteria: * Other active cancer or bone infection. * Chemotherapy or change in hormone therapy since the last PSA assay * Contraindication to MRI without contrast agent (claustrophobia, pace maker, metallic foreign body, some cardiac valves). Metallic joint prostheses are NOT a contraindication. * Allergic reaction to radiopharmaceuticals that will be used. * Patient who seems not capable of staying in the gantry of the machines during the examinations without moving.
References
Publications (1)
- DERIVEDGauthe M, Zarca K, Aveline C, Lecouvet F, Balogova S, Cussenot O, Talbot JN, Durand-Zaleski I. Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France. BMC Med Imaging. 2020 Mar 2;20(1):25. doi: 10.1186/s12880-020-00425-y. PMID 32122345